TrialCephalalgia : an international journal of headache2021

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.

Messoud Ashina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.